Zoetis Inc. (NYSE:ZTS) Shares Purchased by FourThought Financial Partners LLC

FourThought Financial Partners LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,237 shares of the company’s stock after purchasing an additional 570 shares during the period. FourThought Financial Partners LLC’s holdings in Zoetis were worth $3,007,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Vestmark Advisory Solutions Inc. lifted its holdings in Zoetis by 0.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 20,604 shares of the company’s stock worth $4,067,000 after acquiring an additional 153 shares during the last quarter. AJOVista LLC acquired a new position in shares of Zoetis during the fourth quarter valued at $136,000. Sapient Capital LLC acquired a new stake in shares of Zoetis in the 4th quarter worth about $305,000. Axxcess Wealth Management LLC lifted its position in Zoetis by 4.3% in the 4th quarter. Axxcess Wealth Management LLC now owns 8,368 shares of the company’s stock valued at $1,652,000 after purchasing an additional 345 shares during the last quarter. Finally, Power Wealth Management LLC bought a new position in Zoetis in the 4th quarter worth about $818,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 0.1 %

NYSE ZTS traded down $0.16 on Friday, hitting $167.07. 3,007,125 shares of the company were exchanged, compared to its average volume of 4,607,073. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company’s 50 day moving average price is $168.88 and its 200-day moving average price is $178.84. The firm has a market capitalization of $76.41 billion, a P/E ratio of 32.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS. Analysts predict that Zoetis Inc. will post 5.78 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 in the last three months. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Stifel Nicolaus decreased their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group upped their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Finally, Barclays dropped their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.